Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911
| Autor: | J. Alfred Witjes, Willem Oosterlinck, Maurizio Brausi, George van Andel, Wim J. Kirkels, Theo M. de Reijke, Jorg R. Oddens, Cees van de Beek, Richard Sylvester, Stephen Prescott |
|---|---|
| Přispěvatelé: | Urology |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Urology Urinary system 030232 urology & nephrology Maintenance Chemotherapy 03 medical and health sciences 0302 clinical medicine Adjuvants Immunologic SDG 3 - Good Health and Well-being Internal medicine medicine Humans Neoplasm Invasiveness Stage (cooking) Aged Neoplasm Staging Carcinoma Transitional Cell Bladder cancer business.industry Carcinoma in situ Age Factors Cancer Middle Aged medicine.disease Surgery Discontinuation Urinary Bladder Neoplasms Withholding Treatment 030220 oncology & carcinogenesis Toxicity BCG Vaccine Female business BCG vaccine |
| Zdroj: | BJU International, 118(3), 423-428. Wiley-Blackwell Publishing Ltd BJU international, 118(3), 423-428. Wiley-Blackwell |
| ISSN: | 1464-4096 |
| DOI: | 10.1111/bju.13474 |
| Popis: | Objective To determine the relationship of age to side-effects leading to discontinuation of treatment in patients with stage Ta–T1 non-muscle-invasive bladder cancer (NMIBC) treated with maintenance bacille Calmette–Guerin (BCG). Patients and Methods We evaluated toxicity for 487 eligible patients with intermediate- or high-risk Ta–T1 (without carcinoma in situ) NMIBC randomised to receive 3 years of maintenance BCG therapy (247 BCG alone and 240 BCG + isoniazid) in European Organisation for Research and Treatment of Cancer Genito-Urinary Group trial 30911. The percentage of patients who stopped for toxicity and the number of treatment cycles that they received were compared in four age groups, ≤60, 61–70, 71–75 and >75 years, using the Mantel–Haenszel chi-square test for trend. Results The percentage of patients stopping BCG for toxicity was 17.9% in patients aged ≤60 years, 21.9% in patients aged 61–70 years, 22.9% in patients aged 71–75 years, and 16.4% in patients aged >75 years (P = 0.90). For both systemic and local side-effects, there was likewise no significant difference. Conclusion In patients with intermediate- and high-risk Ta–T1 NMIBC treated with BCG, no differences in toxicity as a reason for stopping treatment were detected based on patient age. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text